Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

Nature

Volumn 552, Issue , 2017, Pages 116-120

  Germano, Giovanni ^a,b   Lamba, Simona ^a   Rospo, Giuseppe ^a   Barault, Ludovic ^a,b   Magri, Alessandro ^a,b   Maione, Federica ^a   Russo, Mariangela ^a,b   Crisafulli, Giovanni ^a,b   Bartolini, Alice ^a   Lerda, Giulia ^a,b   Siravegna, Giulia ^a,b   Mussolin, Benedetta ^a   Frapolli, Roberta ^c   Montone, Monica ^a   Morano, Federica ^d   De Braud, Filippo ^d,e   Amirouchene Angelozzi, Nabil ^a,f   Marsoni, Silvia ^a   D'Incalci, Maurizio ^c   Orlandi, Armando ^g   Giraudo, Enrico ^a,h   Sartore Bianchi, Andrea ⁱ   Siena, Salvatore ^e,i   Pietrantonio, Filippo ^d   Di Nicolantonio, Federica ^a,b   Bardelli, Alberto ^a,b   more..

^a IRCCS Candiolo   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^g FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GILVETMAB; IRINOTECAN; MUTL PROTEIN HOMOLOG 1; NEOANTIGEN; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CANCER ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; MLH1 PROTEIN, MOUSE;

ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; DNA; GENETIC ANALYSIS; GENETIC ENGINEERING; GROWTH; HOMOLOGY; MOLECULAR ANALYSIS; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER TRANSPLANTATION; CARCINOGENESIS; CLINICAL ARTICLE; COLON CARCINOMA; CRISPR-CAS9 SYSTEM; CT26 CELL LINE; FEMALE; GENE EDITING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MC-38 CELL LINE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR CLONING; MOLECULAR PATHOLOGY; MOUSE; MUTATIONAL LOAD; NONHUMAN; PANCREATIC DUCTAL CARCINOMA CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; TS/A CELL LINE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; DEFICIENCY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE; TUMOR ESCAPE;

MUS;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL PROLIFERATION; DNA MISMATCH REPAIR; FEMALE; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MUTL PROTEIN HOMOLOG 1; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; TUMOR ESCAPE;

EID: 85037841016     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24673     Document Type: Article

References (44)

1. Lord, C. J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287-294 (2012).
2. Vilar, E. & Gruber, S. B. Microsatellite instability in colorectal cancer-the stable evidence. Nat. Rev. Clin. Oncol. 7, 153-162 (2010).
3. Orthwein, A. et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature 528, 422-426 (2015).
4. Rayner, E. et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat. Rev. Cancer 16, 71-81 (2016).
5. Ponti, G., Castellsagué, E., Ruini, C., Percesepe, A. & Tomasi, A. Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome. Clin. Genet. 87, 507-516 (2015).
6. Jiricny, J. Postreplicative mismatch repair. Cold Spring Harb. Perspect. Biol. 5, a012633 (2013).
7. Woerner, S. M. et al. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors. Mol. Carcinog. 54, 1376-1386 (2015).
8. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
9. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
10. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413 (2017).
11. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
12. Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433-438 (2016).
13. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
14. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016).
15. Juneja, V. R. et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 214, 895-904 (2017).
16. Chew, W. L. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat. Methods 13, 868-874 (2016).
17. Bailey, J. M. et al. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells. Oncogene 35, 4282-4288 (2016).
18. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
19. Castle, J. C. et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 15, 190 (2014).
20. Bardelli, A. et al. Carcinogen-specific induction of genetic instability. Proc. Natl Acad. Sci. USA 98, 5770-5775 (2001).
21. Fink, D., Aebi, S. & Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4, 1-6 (1998).
22. Cahill, D. P. et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin. Cancer Res. 13, 2038-2045 (2007).
23. Yip, S. et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15, 4622-4629 (2009).
24. Medico, E. et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun. 6, 7002 (2015).
25. Sartore-Bianchi, A. et al. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. Eur. J. Cancer 71, 43-50 (2017).
26. Lee, S. Y. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 3, 198-210 (2016).
27. Cahill, D. P., Codd, P. J., Batchelor, T. T., Curry, W. T. & Louis, D. N. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin. Neurosurg. 55, 165-171 (2008).
28. Calegari, M. A. et al. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. Br. J. Cancer 116, 1279-1286 (2017).
29. Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288 (2002).
30. Maletzki, C., Schmidt, F., Dirks, W. G., Schmitt, M. & Linnebacher, M. Frameshiftderived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers. Eur. J. Cancer 49, 2587-2595 (2013).
31. Gilles, M. E. et al. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Res. 76, 7181-7193 (2016).
32. Corbett, T. H., Griswold, D. P. Jr, Roberts, B. J., Peckham, J. C. & Schabel, F. M. Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35, 2434-2439 (1975).
33. Nanni, P., de Giovanni, C., Lollini, P. L., Nicoletti, G. & Prodi, G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1, 373-380 (1983).
34. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
35. Maione, F. et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J. Clin. Invest. 122, 1832-1848 (2012).
36. Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43-51 (2015).
37. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
38. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
39. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
40. Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511-517 (2016).
41. Wang, K. et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 38, e178 (2010).
42. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
43. Gaide, O. et al. Common clonal origin of central and resident memory T cells following skin immunization. Nat. Med. 21, 647-653 (2015).
44. Chen, L., Liu, P., Evans, T. C. & Ettwiller, L. M. DNA damage is a pervasive cause of sequencing errors, directly confounding variant identification. Science 355, 752-756 (2017).